| Interim Analysis Supports Continuation Of Cell Genesys' VITAL-1 Phase ...
Cell Genesys, Inc. (Nasdaq: CEGE) announced that the Independent Data Monitoring Committee (IDMC) for VITAL-1, the first of two ongoing Phase 3 clinical trials of GVAX immunotherapy for prostate cancer, has completed a pre-planned interim analysis and has recommended that the study continue. This event-driven interim analysis was designed to determine whether the study should continue to completion and took place in the time frame originally estimated. As is customary to preserve study blinding, the IDMC provided no information to the company other than the recommendation to continue the trial.
"The IDMC's recommendation to continue with the VITAL-1 trial represents an important step forward in the Phase 3 development of GVAX immunotherapy for prostate cancer and in our effort to make this product available as a new treatment option for men with prostate cancer," stated Robert Dow, MBChB, chief medical officer of Cell Genesys.
ArcMesa Educators Announces First Interdisciplinary Prostate Cancer ...
MONROW TOWNSHIP, N.J., Oct. 29 /PRNewswire/ -- ArcMesa Educators, a multi- accredited provider of award winning continuing education courses, is proud to announce its first annual Interdisciplinary Prostate Cancer Congress (IPCC) taking place in March 2008. This unique congress seeks to foster a paradigm shift to an integrated prostate cancer care team approach among two physician groups actively involved in treatment, namely the oncologist and the urologist. It will be part of a broadening initiative of medical education programming focused on the same theme by identifying and assessing rapid advancements in therapeutics and new treatment modalities with the goal of improved patient outcomes. IPCC also marks another bold step in ArcMesa Educators' strategic realignment with its dedicated focus to provide cutting edge information in an environment and format conducive to the educational needs of physicians.
Semafore's SF1126 Exhibits Antitumor And Antiangiogenic Activity
Semafore Pharmaceuticals Inc. announced that a paper published in Cancer Research (2008; Vol. 68, Issue 1: 206-215) reports that SF1126, the company's lead product candidate, exhibits antitumor and antiangiogenic activity.
The paper, entitled "A Vascular Targeted Pan Phosphoinositide 3-Kinase Inhibitor Prodrug, SF1126, with Antitumor and Antiangiogenic Activity," is based on preclinical studies conducted by Semafore and collaborators at Children's Healthcare of Atlanta, Emory University School of Medicine, and M.D. Anderson Cancer Center. Phosphoinositide 3-kinase (PI3K) is a powerful pathway and an emerging cancer target for inhibition. In the studies reported, SF1126 showed favorable pharmacokinetics and pharmacodynamic effects as indicated by inhibition of downstream signaling elements both in vitro and in vivo.
|
